Syngene International Ltd Share Price

Healthcare

NSE: SYNGENE Small Cap ISIN: INE398R01022

As on 19 November 2025 at 01:32 IST

₹646.05

-6.10

(-0.94%)

Sell Buy

Syngene International Q1 FY26 Results:

Profit rose 14.5% to ₹87 crores, compared to ₹76 crores in Q1 FY25. Total income in Q1 FY26 increased 10% to ₹892 crores from ₹808 crores in the same period last year.

About Syngene International Ltd

Syngene International Ltd is a contract research and manufacturing organization (CRMO). It provides integrated research, development, and manufacturing services. These services are globally offered for pharmaceutical, biotechnology, nutrition, and speciality chemical companies. The company was founded in 1993. Syngene International has grown to become one of India's leading CRAMS players with prestigious international clients. The headquarters of the company is located in Bangalore, Karnataka. Syngene's main services include integrated drug discovery, dedicated R&D centres, biologics manufacturing, small molecule development, and clinical development services. The company operates in the Healthcare Services sector. +

Over 1 Month

2.11%

Over 6 Months

1.58%

Over 1 Year

-22.62%

Over 3 Years

6.69%

Syngene International Ltd Summary

Close ₹652.15

Open ₹654.55

High ₹658.50

Low ₹649.20

Volume 4,86,418

Net Turnover (in Cr) ₹31.8

52Wk High ₹960.60

52Wk Low ₹599.55

52Wk High / Low

599.55

960.60

Syngene International Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹26,277.69

EPS (TTM) 10.86

Book Value (BV) 114.67

Div. Yield 0.19 %

P/E (TTM) 60

Price/Book Value 5.68

Delivery % 54.67 %

Face Value 10

Key Ratios

PE Ratio 62.43

PB Ratio 6.30

EV to Sales 8.56

PEG Ratio 241.40

ROA 8.99

ROE 10.60

Debt-Equity 0.07

Net Profit Margin 13.87

Operating Profit Margin 30.24

Syngene International Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	3,714.20	3,579.20	3,263.80	2,657	2,248.90
Total Expenses	3,086.30	2,947.30	2,670.20	2,141.90	1,814.70
Profit Before Tax	659.90	620.80	593.60	484.40	469.20
Profit After Tax	496.20	510	464.40	395.80	404.90
Operating Profit After Depreciation	681	679.10	638.80	539.20	461.90

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	2,772.10	2,810.20	2,618.80	2,354.30	2,163.40
Total Non Current Assets	4,508.60	4,192.60	3,405.70	3,357.90	3,076.50
Total Current Assets	2,287.30	1,959	2,425.30	2,205.90	1,806.70
Total Assets	6,795.90	6,151.60	5,831	5,563.80	4,883.20
Total Shareholder's Fund	4,726.80	4,257.70	3,618	3,297.60	2,821.40

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	1,167.60	1,042.10	823.50	580.60	701.20
Net Cash Used In Investing Activities	-744.40	-494.50	-653.30	-610.80	-628.90
Net Cash Used In Financing Activities	-141.80	-551.40	-342.50	-31.30	58

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	3,443.80	3,291.10	3,264.40	2,709	2,244
Total Expenses	2,854.20	2,722.70	2,663.50	2,196.60	1,811.60
Profit Before Tax	621.60	557.30	600.90	481.70	467.40
Profit After Tax	468	466.50	473	393.80	403.70
Operating Profit After Depreciation	620.80	597.90	646.10	536.50	460.10

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	2,211.60	2,278.10	2,211.80	2,354.30	2,163.40
Total Non Current Assets	4,373	3,982	2,963.70	3,357.20	3,076.50
Total Current Assets	2,033.90	1,851.90	2,884.30	2,203.60	1,801
Total Assets	6,406.90	5,833.90	5,848	5,560.80	4,877.50
Total Shareholder's Fund	4,638.90	4,191.50	3,618.90	3,292	2,818.30

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	1,113.80	913.40	838.40	582.20	698
Net Cash Used In Investing Activities	-810.40	-382.60	-685.10	-610.80	-628.90
Net Cash Used In Financing Activities	-136.50	-536.30	-340.20	-31.30	58

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	910.60	874.50	1,018	943.70	891
Total Expenses	711.10	668.10	674.40	660.10	646.20
Profit Before Tax	85.20	101.30	240.50	180.80	137.30
Profit After Tax	67.10	86.70	183.30	131.10	106.10
Operating Profit after Depreciation	214.90	224.10	362.50	301.90	261.30

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	830.10	799.30	948.40	877.10	821.30
Total Expenses	652.60	631.20	638.40	626.30	612.70
Profit Before Tax	84.20	84.20	228.70	169.80	124.30
Profit After Tax	66.20	74	174.40	123.10	96.60
Operating Profit after Depreciation	191.70	184.70	328.40	268.80	225

Syngene International Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 648.07

S2 643.98

S3 638.77

Pivot 653.28

R1 657.37

R2 662.58

R3 666.67

Moving Average

20 SMA 648.61

50 SMA 645.17

100 SMA 652.75

200 SMA 667.08

Syngene International Ltd Corporate Actions

Syngene International Ltd

₹1.25/Share

Announcement Date 27 Jun 2025

Record Date 27 Jun 2025

Div Yield 12%

AGM Date: 21 Jul 2021

Outcome of the Board Meeting Record date fixed as Wednesday, July 14, 2021 for the purpose of holding the 28th Annual General Meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of newspaper advertisement published in Financial Express (English Language) and Vijayavani (Kannada Language), in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating that the 28th Annual General Meeting of the Company will be held on Wednesday, July 21, 2021 at 3:30 pm IST through Video Conferencing / Other Audio Visual Means. (As per BSE Announcement Dated on 25/06/2021) We wish to inform you that the 28th AGM of the Company will be held on Wednesday, July 21, 2021 at 3:30 pm IST through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM'). In this regard, please find enclosed the Notice of the 28th AGM of the Company, which is being circulated to the shareholders through electronic mode. The Notice is also available on the Company's website at https://www.syngeneintl.com/investors/share-holder-services/. (As Per BSE Announcement Dated 26.06.2021) Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. John M M Shaw (DIN: 00347250) (Non-Executive, Non- Independent Director), vide his letter dated July 20, 2021 has communicated his intention to step down from the Board of Directors of the Company due to health reasons with effect from conclusion of the Annual General Meeting of the Company scheduled on July 21, 2021. (As Per BSE Announcement dated on 21.07.2021) With reference to the above-mentioned subject, we hereby enclose the proceedings of the 28th Annual General Meeting held on Wednesday, July 21, 2021 at 03:30 p.m. through video conferencing.(As Per BSE Announcement Dated on 7/22/2021 3:14:09 PM) Subject: Subject: Voting results under Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We hereby submit the results of voting concluded at the 28th Annual General Meeting of Syngene International Limited held on July 21, 2021, on all the resolutions set forth in the AGM Notice dated June 22, 2021. We would like to inform you that resolution nos. 1 to 4 have been approved with the requisite majority by the shareholders of the Company. The details of votes cast by shareholders are given in the attached Annexure A. As required under Section 108 of the Companies Act, 2013 read with Rule 20(4) of the Companies (Management and Administration) Rules, 2014, as amended, the consolidated Scrutinizer's Report on the remote e-voting and voting through Insta-poll is also enclosed. Pursuant to Reg 30 of SEBI LODR we wish to inform you the following appointment/reappointment passed by the shareholders at the 28th AGM held on July 21, 2021. 1. Appointment of Dr Kush Parmar (DIN: 09212020) as the Independent Director on the Board of Directors of the Company, for a first term from the date of appointment by the Board (22nd June, 2021) until the conclusion of the 31st AGM of the Company proposed to be held in 2024. The brief profile of Dr Kush Parmar is enclosed as Annexure A. 2. Re-appointment of M/s B S R & Co. LLP, Chartered Accountants, bearing Registration Number 101248W/W-100022 as the Statutory Auditors of the Company for a term of five consecutive years from the conclusion of this (28th) Annual General Meeting until the conclusion of AGM to be held in the year 2026 on such remuneration as may be fixed by the Board of Directors in consultation with the Statutory Auditors of the Company. (AS Per BSE Announcement Dated on 23.07.2021)

AGM Date: 20 Jul 2022

Outcome of the Board Meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of newspaper advertisement published in Financial Express (English Language) and Vijayavani (Kannada Language), in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating that the 29th Annual General Meeting of the Company will be held on Wednesday, July 20, 2022 at 3:30 pm IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM).The above information will also be available on the website of the Company at www.syngeneintl.com. Request you to kindly take this intimation on record and acknowledge. (As Per BSE Announcement Dated on 27/06/2022) In continuation to our letter dated June 27, 2022 on Notice of the 29th AGM, we wish to inform you that the Company has completed dispatching of Notice of the 29th AGM and Annual Report 2021-22 through e-mail on June 27, 2022 to eligible members who have registered their e-mail ID's with the Company/Depositories. Please find enclosed the copies of newspaper advertisement published in Financial Express (English Language) on June 28, 2022 and Vijayavani, Bengaluru Edition (Kannada Language) on June 28, 2022 (As Per BSE Announcement Dated on 28.06.2022) Corrigendum to the Annual Report for FY 2021-22. (As Per BSE Announcement Dated on 06.07.2022) Syngene International Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 22.07.2022) With reference to the above-mentioned subject, we hereby enclose the proceedings of the 29th Annual General Meeting ('AGM') held on Wednesday, July 20, 2022 at 03:30 p.m. through video conferencing. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the shareholders at the 29th Annual General Meeting ('AGM') held on July 20, 2022 approved the re-appointment of Ms. Sharmila Abhay Karve (DIN: 05018751) as the Independent Director on the Board of Directors of the Company, for a second term of five years commencing from the date of 29th AGM i.e. July 20, 2022. The consolidated Scrutinizer's Report on the remote e-voting and voting through Insta-poll on 29th AGM held on July 20, 2022. Voting results under Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated 21.07.2022)

AGM Date: 26 Jul 2023

Cconvening of the 30th Annual General Meeting of the Company on Wednesday, July 26, 2023 We wish to inform you that the Company has completed dispatching of Notice of the 30th AGM and Annual Report 2022-23 through email on July 4,2023 to eligible members who have registered their email ID''s with the Company / Depository Participant(s) . Please find enclosed the copies of the newspaper advertisement published in Financial Express (English language) on July 5,2023 and Vijayavani, Bengaluru edition (Kannada Language) on July 5,2023. (As Per BSE Announcement Dated on 05.07.2023) Proceedings of the 30th Annual General Meeting. (As per BSE Announcement Dated on 26/07/2023) The Consolidated Scrutinizer''s Report on the remote e-voting and voting through Insta-poll 30th AGM on July 26, 2023. Voting Results under Regulation 44(3) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. (As Per BSE Announcement Dated on 28.07.2023)

AGM Date: 24 Jul 2024

Convening of the 31st Annual General Meeting of the Company on Wednesday, July 24, 2024. Copy of the notice convening the Annual General Meeting will be sent in due course Notice of the 31st Annual General Meting ('AGM') (As Per BSE Announcement Dated on: 02/07/2024) Proceedings of the 31st Annual General Meeting. (As Per BSE Announcement Dated on: 24/07/2024)

AGM Date: 23 Jul 2025

Approved convening of the 32nd Annual General Meeting of the Company on Wednesday, July 23, 2025. Copy of the notice convening the Annual General Meeting will be sent in due course. Notice of 32nd Annual General Meeting ('AGM') scheduled on Wednesday, July 23, 2025 (As Per BSE Announcement Dated on: 28/06/2025) Proceedings of the 32nd Annual General Meeting (As Per BSE Announcement Dated on :23.07.2025) We are enclosing herewith the scrutinizer''s report and voting result with respect to 32nd AGM of the Company held on July 23, 2025. (As Per BSE Announcement Dated on :24.07.2025)

Syngene International Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Max Healthcare Institute Ltd	₹1,121.90	₹1,09,099.45
Apollo Hospitals Enterprise Ltd	₹7,488.40	₹1,07,671.70
Fortis Healthcare Ltd	₹944.15	₹71,279.37
Narayana Hrudayalaya Ltd	₹2,027.90	₹41,442.33
Aster DM Healthcare Ltd	₹678.35	₹35,146.74

Syngene International Ltd Top Mutal Funds Invested

Fund Name	AUM
Mirae Asset Focused Fund	3.37%
Nippon India Focused Fund	2.77%
ICICI Pru ELSS Tax Saver Fund	1.65%
DSP ELSS Tax Saver Fund	1.41%
DSP Large & Mid Cap Fund	1.33%

Syngene International Ltd News

Syngene International schedules board meeting

On 5 November 2025

10 Oct 2025, 10:13 am

Syngene International declare Quarterly Result

On 23 July 2025

12 Jul 2025, 10:08 am

Syngene's Bengaluru-based facility gets 'NAi' status from US FDA

Syngene International said that the United States Food and Drug Administration (US FDA) conducted a good clinical practices (GCP) compliance inspection of the company's facility located at Semicon Park, Bengaluru, from 09 to 13 of June 2025.

14 Jun 2025, 02:28 pm

Syngene slides on tepid results and toned-down forecast

Syngene International dropped 12.83% to Rs 653.85 after its lacklustre Q4 performance and a cautious FY26 outlook spooked investors.

24 Apr 2025, 04:22 pm

Syngene International Ltd leads losers in 'A' group

Nava Ltd, 360 ONE WAM Ltd, KFin Technologies Ltd and Can Fin Homes Ltd are among the other losers in the BSE's 'A' group today, 24 April 2025.

24 Apr 2025, 03:00 pm

Syngene International Ltd Stock Analysis

Annual revenue for Syngene International Ltd increased by 4.64% to ₹3,443.80 crore in FY 2025 from ₹3,291.10 crore in FY 2024.
Annual Net Profit for Syngene International Ltd increased by 0.32% to ₹468 crore in FY 2025 from ₹466.50 crore in FY 2024.
Promoter Shareholding in Syngene International Ltd remains unchanged by 0.00% in the most recent quarter, from 52.68% in June 2025 to 52.68% in September 2025.
Syngene International Ltd delivered a 1-year return of -22.62% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
Syngene International Ltd share price moved down by 0.94% from its previous close of INR ₹652.15. The latest Syngene International Ltd share price is INR ₹646.05.
Syngene International Ltd share price today has been at a low of 643.75 and a high of 653. Over the past 52 weeks, the Syngene International Ltd share price has seen a low of 599.55 and a high of 960.60.

About Syngene International Ltd

Syngene International Ltd is a contract research and manufacturing organization (CRMO). It offers these services for pharmaceutical, nutrition, animal health, and speciality chemical companies. The company provides integrated research, development, and manufacturing services globally. The company falls under the Healthcare Services sector. Syngene specifically focuses on the Contract Research & Manufacturing Services (CRAMS) subsector.
Initiated in 1993, Syngene has been in business for many years. The company is headquartered in Bangalore, Karnataka, India. Syngene was promoted by Biocon Ltd, with Dr. Kiran Mazumdar-Shaw playing a pivotal role in its establishment and growth. Also, he serves as the non-executive chairman of the company. The company is guided by an experienced board of directors. The managerial promoters of the company include:

Jonathan Hunt
Sibaji Biswas
Catherine Rosenberg
Kush Parmar

The promoter shareholding of the company stands at 54.72%. Biocon remains the principal promoter of the company, holding a 54.45% stake in the company.
The main services offered by Syngene include integrated drug discovery services, dedicated R&D centres and biologics manufacturing. It also offers small molecule development manufacturing and clinical development services. The company operates state-of-the-art research facilities that cater to global pharmaceutical giants.
Syngene is among the leading players in India's CRAMS sector. However, it is not the top player in terms of market capitalization. The company has established itself as one of the most respected names in the industry, with a strong global client base. This includes Bristol Myers Squibb, Amgen, and GSK.
The company's registered office is located at Biocon Park, Bommasandra Industrial Area, Phase IV, Bangalore - 560099, Karnataka. The registrar and transfer agent for Syngene is KFin Technologies Limited.

International Base of the Company

Syngene International Ltd. has established itself as a prominent global contract research and manufacturing organization. The company serves its clients across many continents. Since its start in 1993, the company has systematically built its international presence by focusing on delivering high-quality research, development, and manufacturing services to pharmaceutical and biotechnology companies worldwide.
The company's international footprint is primarily demonstrated through its impressive client roster. This includes several global pharmaceutical giants. Bristol Myers Squibb is one of the world's largest pharmaceutical companies. It has had a long-standing relationship with Syngene, operating a dedicated research facility in Bangalore. The partnership of these companies began in 2007 and has grown significantly. This showcases Syngene's ability to meet international quality standards and regulatory requirements.
Syngene International has collaboration with Amgen and another major global biotechnology company. This further strengthens its international credentials. The company operates a dedicated R&D centre for Amgen, providing integrated drug discovery and development services. This partnership demonstrates Syngene's capability to handle complex research projects and meet the exacting standards of international clients.
The company's relationship with GlaxoSmithKline (GSK) represents another significant international partnership. Through this collaboration, Syngene provides various research and development services. This contributes to GSK's global drug discovery and development programs. These partnerships with leading pharmaceutical companies have helped Syngene build a strong reputation in the global CRAMS market.
Syngene's international operations are supported by its state-of-the-art facilities in India that conform to global standards. The company's research and manufacturing facilities are certified by international regulatory authorities. These authorities include the US FDA and EMA (European Medicines Agency), which enables the company to serve its clients worldwide. This regulatory compliance has been crucial in attracting and retaining international clients.
The company has also developed expertise in various therapeutic areas that are relevant to global markets. These therapeutic areas include oncology, cardiovascular, diabetes, and inflammatory diseases. This broad therapeutic coverage allows Syngene to cater to diverse international client requirements and participate in global drug discovery and development programs.
Syngene's international business model is built on providing integrated services across the drug discovery and development value chain. The company offers end-to-end solutions from early-stage research to commercial manufacturing. These solutions appeal to international clients looking to outsource their R&D and manufacturing needs. This comprehensive service offering has helped Syngene secure long-term contracts with international clients.
The company's scientific talent pool comprises highly qualified researchers and scientists. Many of these researchers and scientists have international exposure and experience, which further strengthens the company's ability to serve global clients. This expertise allows Syngene to undertake complex research projects and deliver results that meet international standards.
Syngene International's success in building a strong international presence can be attributed to its focus on quality, regulatory compliance, comprehensive service offerings, and strong client relationships. The company has successfully positioned itself as a reliable partner for global pharmaceutical and biotechnology companies. This is evidenced by its long-term partnerships with industry leaders like Bristol Myers Squibb, Amgen, and GSK.
Plus, the company is committed to maintaining high-quality standards and investing in cutting-edge facilities. This suggests that it will continue to strengthen its position in the global CRAMS market. The company's international focus has helped to grow its business. Also, this has also contributed to establishing India as a preferred destination for pharmaceutical research and manufacturing services.